盟科藥業(688373.SH):MRX-5已基本完成臨牀前研究
格隆匯9月21日丨有投資者向盟科藥業(688373.SH)提問:MRX-5是公司儲備的另一個重要品種嗎?
盟科藥業回覆:MRX-5屬於新型抗耐藥非結核分枝桿菌感染新藥。非結核分枝桿菌(Non-tuberculous Mycobacteria,NTM)是指除了結核分枝桿菌複合羣和麻風分枝桿菌之外的一大類分枝桿菌。迄今為止,已經發現了190多種NTM菌種及其14個亞種,NTM病的發病率和患病率呈持續增長的態勢,且藥物治療的療程長、不良反應多、療效和預後欠佳,特別是耐藥患者的治療面臨挑戰。公司的MRX-5對大多數常見的NTM菌都具有良好的抗菌活性,且動物毒物顯示藥物具有良好的安全性,有望為NTM病患者提供一種全新的治療選擇。2023年上半年,MRX-5已基本完成臨牀前研究,計劃於2023年下半年在澳大利亞開展I期臨牀研究。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.